You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Angiotensin Converting Enzyme-Inhibitor (ACE-I) or Angiotensin Receptor Blocker (ARB) Therapy--Diabetes of LVSD (LVEF

Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have diabetes OR a current or prior Left Ventricular Ejection Fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy. 

Date Reviewed: November 4, 2018

Measure Info

MIPS 118NQF 0066CMS 118NQF EndorsedCQMC Core Measure
Measure Type: 
Measure Steward: 
American Heart Association/American Stroke Association
Clinical Topic Area: 
Coronary Artery Disease

Care Setting: 
Data Source: 
Registry Data

ACP supports MIPS measure ID# 118 (NQF ID# 0066): “Coronary Artery Disease: Angiotensin Converter Enzyme-Inhibitor (ACE-I) or Angiotensin Receptor Blocker (ARB) Therapy—Diabetes or LVSD (LVEF <40%)” because implementation will likely promote appropriate use of ACE-I and ARB therapy in patients who are diagnosed with CAD, the developer cites clinical recommendations of the American College of Cardiology (ACC)/American Heart Association (AHA)/American College of Physicians (ACP) for the “Management of Stable Ischemic Heart Disease” to form the basis of the measure, the measure specifications are well-defined, and data collection is feasible and burden is acceptable for clinicians report this measure. While we support this measure, we note that the measure is close to being topped out. Performance data suggests that 81% of clinicians who reported this measure in 2014 adhere to the interventions described in the specifications.